The only update for patients with stage IV NSCLC without driver alterations is that patients who have HER2-overexpressing (IHC 3+) disease and good performance status can receive trastuzumab ...

New research delves into the DNA details and chromatin structures that may predict prognosis in early-stage lung ...

Some recommend scoring solid intraductal carcinoma as Gleason 5, but the cancer is linked to significantly poorer outcomes.